1.
Recognition, Pathogenesis, and Treatment of Different Stages of Nephropathy in Patients With Type 2 Diabetes Mellitus
by Bakris, George L., MD
Mayo Clinic proceedings, 2011, Vol.86 (5), p.444-456
2.
Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis...
by Bakris, George L, Dr, Prof
The Lancet (British edition), 2010, Vol.375 (9721), p.1173-1181
3.
MY APPROACH to the elderly patient with resistant hypertension
by Bakris, George L
Trends in cardiovascular medicine, 2018-01, Vol.28 (1), p.79-80
4.
Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial
by Weber, Michael A, Prof
The Lancet (British edition), 2013, Vol.381 (9866), p.537-545
5.
Predictors of Hyperkalemia Risk following Hypertension Control with Aldosterone Blockade
by Khosla, Nitin
American journal of nephrology, 2009-11, Vol.30 (5), p.418-424
6.
Spironolactone for resistant hypertension—hard to resist?
by Sternlicht, Hillel
The Lancet (British edition), 2015, Vol.386 (10008), p.2032-2034
7.
Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitors
by Steingart, Richard M., MD
The American heart journal, 2012, Vol.163 (2), p.156-163
8.
EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular saf...
by White, William B
The American heart journal, 2011-10, Vol.162 (4), p.620-626.e1
9.
Chronic Kidney Disease Associated Mortality in Diastolic Versus Systolic Heart Failure: A Propensity Matched Study
by Ahmed, Ali, MD, MPH
The American journal of cardiology, 2007, Vol.99 (3), p.393-398
10.
Mechanisms Contributing to Adverse Cardiovascular Events in Patients with Type 2 Diabetes Mellitus and Stage 4 Chronic Kidney Disease Treated with Bardoxolone Methyl
by Chin, Melanie P
American journal of nephrology, 2014-07, Vol.39 (6), p.499-508
11.
Catheter-Based Renal Denervation for Resistant Hypertension: Will It Ever Be Ready for “Prime Time”?
by Laffin, Luke J
American journal of hypertension, 2017-09-01, Vol.30 (9), p.841-846
12.
In search for the ‘sweet spot’ for blood pressure level in diabetes
by Yamout, Hala
Heart (British Cardiac Society), 2014-09, Vol.100 (18), p.1404-1405
13.
Chronic kidney disease, prevalence of premature cardiovascular disease, and relationship to short-term mortality
by McCullough, Peter A., MD, MPH
The American heart journal, 2008, Vol.156 (2), p.277-283
14.
Renin-angiotensin blockade and kidney disease
by Sarafidis, Pantelis A
The Lancet (British edition), 2008, Vol.372 (9638), p.511-512
15.
New Potassium Binders for the Treatment of Hyperkalemia: Current Data and Opportunities for the Future
by Pitt, Bertram
Hypertension (Dallas, Tex. 1979), 2015-10, Vol.66 (4), p.731-738
16.
Lowering blood pressure limits in patients with type 2 diabetes: Is it still warranted?
by Bakris, George L
Journal of diabetes and its complications, 2013, Vol.27 (5), p.415-416
17.
High screen failure rate in patients with resistant hypertension: Findings from SYMPLICITY HTN-3
by Waksman, Ron
The American heart journal, 2017-10, Vol.192, p.76-84
18.
Rationale and Trial Design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: The Occurrence of Renal Events (BEACON)
by de Zeeuw, Dick
American journal of nephrology, 2013-04, Vol.37 (3), p.212-222
19.
Ischemic cardiac outcomes and hospitalizations according to prior macrovascular disease status in patients with type 2 diabetes and recent acute coronary syndrome from the Examinat...
by Shimada, Yuichi J
The American heart journal, 2016-05, Vol.175, p.18-27
20.
The Antinatriuretic Effect of Insulin: An Unappreciated Mechanism for Hypertension Associated with Insulin Resistance?
by Sarafidis, Pantelis A
American journal of nephrology, 2007-03, Vol.27 (1), p.44-54
